Objective:To study the improvement of Chaishao Jieyu decoction combined with Pingxiao capsule on the mental state、immune function and endometrium of patients with luminal breast cancer undergoing endocrine therapy af...Objective:To study the improvement of Chaishao Jieyu decoction combined with Pingxiao capsule on the mental state、immune function and endometrium of patients with luminal breast cancer undergoing endocrine therapy after operation.Methods:60 cases of luminal breast cancer patients after operation,according to the method of random grouping would be divided into the control group and the observation group,each group 30 cases.The control group were treated with tamoxifen.On the basis,the observation group accepted oral administration of Chaishao Jieyu Decoction and Pingxiao capsule.The levels of 5-HT、DA、T lymphocyte subsets、IGF-1 and endometrial thickness were compared.Results:At the end of treatment,the observation group's 5-HT、DA、CD3+、CD4+levels were obviously higher than the control group(P<0.05),the observation group's CD8+levels、IGF-1 levels and endometrial thickness were significantly lower than the control group(P<0.05).Conclusion:Chaishao Jieyu Decoction combined with Pingxiao capsule can significantly improve the mental state、immune function of patients with luminal breast cancer undergoing endocrine therapy after surgery,and inhibit their endometrial thickening,the effect is exact.展开更多
OBJECTIVE:To systematically review the effectiveness and safety of Pingxiao capsule(平消胶囊)adjuvant chemotherapy in the treatment of breast cancer.METHODS:A total of 8 databases including the Cochrane Library,PubMed...OBJECTIVE:To systematically review the effectiveness and safety of Pingxiao capsule(平消胶囊)adjuvant chemotherapy in the treatment of breast cancer.METHODS:A total of 8 databases including the Cochrane Library,PubMed,EMBASE,Engineering Index,Chinese Biomedical Literature Database,Wanfang database,China National Knowledge Infrastructure Database,and China Science and Technology Journal Database were searched for the Randomized Controlled Trials(RCTs)of Pingxiao capsule combined with chemotherapy in the treatment of breast cancer published before June 2022.Two researchers independently screened the literature,extracted data,and evaluated the risk of bias.R language was used for estimating risks of bias of included studies,data analysis,and plotting.RESULTS:A total of 15 RCTs involving 1272 patients were included in this study.Meta-analysis results indicated that compared with chemotherapy alone,Pingxiao capsule combined with chemotherapy could significantly improve breast cancer patients'objective response rate of breast cancer patients[rate ratio(RR)=1.35,95%confidence interval(CI)(1.12,1.63),P=0.0017],the disease control rate[RR=1.16,95%CI(1.08,1.25),P<0.0001],the quality of life[RR=1.42,95%CI(1.16,1.74),P=0.007],and the level of the immune cells[CD3+:standardized mean difference(SMD)=1.42,95%CI(0.76,2.09),P<0.001;CD4+:SMD=1.18,95%CI(0.70,1.66),P<0.001].In addition,Pingxiao capsule combined with chemotherapy can also significantly reduce CD8+level(P<0.0001)and reduce the symptoms of decreased white blood cell count[SMD=0.62,95%CI(0.39,0.85),P<0.0001],and the occurrence of adverse reactions such as gastrointestinal adverse reactions and limb pain(P<0.05).CONCLUSIONS:Pingxiao capsule can significantly improve the efficacy of chemotherapy,the quality of life and immune function of patients,and reduce the clinical side effects caused by chemotherapy.However,highquality randomized clinical trials with large samples are required for further verification of these results.展开更多
OBJECTIVES: To investigate the anticancer effect of Pingxiao capsule(平消胶囊, PXC) on the treatment of breast cancer in vitro and in vivo. METHODS: The inhibition of PXC on cell viability and proliferation was determ...OBJECTIVES: To investigate the anticancer effect of Pingxiao capsule(平消胶囊, PXC) on the treatment of breast cancer in vitro and in vivo. METHODS: The inhibition of PXC on cell viability and proliferation was determined by cell counting kit-8, EdU assay and colony formation assay, respectively. The effect of PXC on cell apoptosis was detected by using flow cytometry. The suppression of PXC on cell migration and invasion was investigated by chamber assay. To investigate the underlying molecular mechanisms, the expression of proteins related to epithelial to mesenchymal transition(EMT) was analyzed by Western blotting in breast cancer cells and by immunohistochemistry in tumor tissues. The anticancer effect of PXC in vivo was evaluated by using MDA-MB-231 xenograft model and 4T1 metastatic breast cancer model. RESULTS: Our results indicated that triple-negative breast cancer(TNBC) cell lines MDA-MB-231 and MDAMB-468 were sensitive to PXC. PXC potently inhibited the proliferation, colony formation, migration, and invasion of MDA-MB-231 and MDA-MB-468 cells in vitro. Then, in vivo MDA-MB-231 xenograft model depicted that PXC significantly reduced tumor size and weight compared with Control. 4T1 lung metastasis model showed that PXC significantly inhibited breast cancer cell spreading to lungs in mice. Mechanistically, PXC inhibited EMT process by reducing cadherin turnover in TNBC. Furthermore, PXC in combination with 8 Gy X-ray treatment obviously promoted the induction of apoptosis, and suppressed cell proliferation. CONCLUSION: PXC could inhibit the proliferation and invasion of TNBC both in vitro and in vivo, and exerted its anti-metastatic effect by regulating cadherin turnover, Furthermore, it sensitized the TNBC cells to radiotherapy. The data supported further development of PXC as an adjuvant-therapy agent for TNBC.展开更多
37例晚期肺癌接受平消胶囊合并化疗药物治疗,与同期单纯化疗的28例晚期肺癌对照,有效率分别是54.0%和35.7%(P>0.05)。治疗组化疗后外周血白细胞减少Ⅱ度以上发生率为43.2%,对照组为78.6%,有显著差异(P<0.01)。部分患者在服用平消...37例晚期肺癌接受平消胶囊合并化疗药物治疗,与同期单纯化疗的28例晚期肺癌对照,有效率分别是54.0%和35.7%(P>0.05)。治疗组化疗后外周血白细胞减少Ⅱ度以上发生率为43.2%,对照组为78.6%,有显著差异(P<0.01)。部分患者在服用平消胶囊前及2疗程后检测外周血 T 细胞亚群及 NK 细胞活性,发现服用平消胶囊2疗程后 OKT_4^+、OKT_4^+/OKT_8^+,均显著升高(P<0.01),NK 活性也明显增高(P<0.05)。提示:平消胶囊对晚期肺癌的化疗可能有一定的增效作用,能减轻血液毒副作用。通过提高化疗后患者外周血 NK 活性及部分纠正 T 细胞亚群的失衡状态,改善患者的细胞免疫功能,起到了补气扶正的作用。展开更多
基金Special project of national traditional Chinese medicine clinical research base of state administration of traditional Chinese medicine(No.JDZX2015057)
文摘Objective:To study the improvement of Chaishao Jieyu decoction combined with Pingxiao capsule on the mental state、immune function and endometrium of patients with luminal breast cancer undergoing endocrine therapy after operation.Methods:60 cases of luminal breast cancer patients after operation,according to the method of random grouping would be divided into the control group and the observation group,each group 30 cases.The control group were treated with tamoxifen.On the basis,the observation group accepted oral administration of Chaishao Jieyu Decoction and Pingxiao capsule.The levels of 5-HT、DA、T lymphocyte subsets、IGF-1 and endometrial thickness were compared.Results:At the end of treatment,the observation group's 5-HT、DA、CD3+、CD4+levels were obviously higher than the control group(P<0.05),the observation group's CD8+levels、IGF-1 levels and endometrial thickness were significantly lower than the control group(P<0.05).Conclusion:Chaishao Jieyu Decoction combined with Pingxiao capsule can significantly improve the mental state、immune function of patients with luminal breast cancer undergoing endocrine therapy after surgery,and inhibit their endometrial thickening,the effect is exact.
基金Henan Province Science and Technology Research Project:Construction of COS Optimization Method for Traditional Chinese Medicine Injection in Treatment of Acute Stroke Based on MMR(No.232102310476)Henan Province Top-notch Talent Training Project of Traditional Chinese Medicine:Construction of A Comprehensive Evaluation Method for Post-Marketing Clinical Safety of Traditional Chinese Medicine Injections Based on MMR(No.2022ZYBJ05)Henan Province Traditional Chinese Medicine Scientific Research Project:Optimization of Core Indicators for Comprehensive Evaluation of Clinical Safety of Traditional Chinese Medicine Injections Based on Analytic Hierarchy Process-Fuzzy Comprehensive Evaluation Method-Taking Shuganning As An Example(No.2022ZY1049)。
文摘OBJECTIVE:To systematically review the effectiveness and safety of Pingxiao capsule(平消胶囊)adjuvant chemotherapy in the treatment of breast cancer.METHODS:A total of 8 databases including the Cochrane Library,PubMed,EMBASE,Engineering Index,Chinese Biomedical Literature Database,Wanfang database,China National Knowledge Infrastructure Database,and China Science and Technology Journal Database were searched for the Randomized Controlled Trials(RCTs)of Pingxiao capsule combined with chemotherapy in the treatment of breast cancer published before June 2022.Two researchers independently screened the literature,extracted data,and evaluated the risk of bias.R language was used for estimating risks of bias of included studies,data analysis,and plotting.RESULTS:A total of 15 RCTs involving 1272 patients were included in this study.Meta-analysis results indicated that compared with chemotherapy alone,Pingxiao capsule combined with chemotherapy could significantly improve breast cancer patients'objective response rate of breast cancer patients[rate ratio(RR)=1.35,95%confidence interval(CI)(1.12,1.63),P=0.0017],the disease control rate[RR=1.16,95%CI(1.08,1.25),P<0.0001],the quality of life[RR=1.42,95%CI(1.16,1.74),P=0.007],and the level of the immune cells[CD3+:standardized mean difference(SMD)=1.42,95%CI(0.76,2.09),P<0.001;CD4+:SMD=1.18,95%CI(0.70,1.66),P<0.001].In addition,Pingxiao capsule combined with chemotherapy can also significantly reduce CD8+level(P<0.0001)and reduce the symptoms of decreased white blood cell count[SMD=0.62,95%CI(0.39,0.85),P<0.0001],and the occurrence of adverse reactions such as gastrointestinal adverse reactions and limb pain(P<0.05).CONCLUSIONS:Pingxiao capsule can significantly improve the efficacy of chemotherapy,the quality of life and immune function of patients,and reduce the clinical side effects caused by chemotherapy.However,highquality randomized clinical trials with large samples are required for further verification of these results.
基金Natural Science Basic Research Plan of Shaanxi Province in China:Chloroguanil Inhibits Breast Cancer Progression by Targeting GHRH/GHRHR Pathway(No.2021JM-030)the Project from the Basic Research Project in Shaanxi Administration of Traditional Chinese Medicine:Inhibitory Effects of Xiakucao(Spica Prunellae Vulgaris)-Maozhuacao(Radix Ranunculi Ternati)Drug Pair on Breast Cancer(No.JCMS028)。
文摘OBJECTIVES: To investigate the anticancer effect of Pingxiao capsule(平消胶囊, PXC) on the treatment of breast cancer in vitro and in vivo. METHODS: The inhibition of PXC on cell viability and proliferation was determined by cell counting kit-8, EdU assay and colony formation assay, respectively. The effect of PXC on cell apoptosis was detected by using flow cytometry. The suppression of PXC on cell migration and invasion was investigated by chamber assay. To investigate the underlying molecular mechanisms, the expression of proteins related to epithelial to mesenchymal transition(EMT) was analyzed by Western blotting in breast cancer cells and by immunohistochemistry in tumor tissues. The anticancer effect of PXC in vivo was evaluated by using MDA-MB-231 xenograft model and 4T1 metastatic breast cancer model. RESULTS: Our results indicated that triple-negative breast cancer(TNBC) cell lines MDA-MB-231 and MDAMB-468 were sensitive to PXC. PXC potently inhibited the proliferation, colony formation, migration, and invasion of MDA-MB-231 and MDA-MB-468 cells in vitro. Then, in vivo MDA-MB-231 xenograft model depicted that PXC significantly reduced tumor size and weight compared with Control. 4T1 lung metastasis model showed that PXC significantly inhibited breast cancer cell spreading to lungs in mice. Mechanistically, PXC inhibited EMT process by reducing cadherin turnover in TNBC. Furthermore, PXC in combination with 8 Gy X-ray treatment obviously promoted the induction of apoptosis, and suppressed cell proliferation. CONCLUSION: PXC could inhibit the proliferation and invasion of TNBC both in vitro and in vivo, and exerted its anti-metastatic effect by regulating cadherin turnover, Furthermore, it sensitized the TNBC cells to radiotherapy. The data supported further development of PXC as an adjuvant-therapy agent for TNBC.
文摘37例晚期肺癌接受平消胶囊合并化疗药物治疗,与同期单纯化疗的28例晚期肺癌对照,有效率分别是54.0%和35.7%(P>0.05)。治疗组化疗后外周血白细胞减少Ⅱ度以上发生率为43.2%,对照组为78.6%,有显著差异(P<0.01)。部分患者在服用平消胶囊前及2疗程后检测外周血 T 细胞亚群及 NK 细胞活性,发现服用平消胶囊2疗程后 OKT_4^+、OKT_4^+/OKT_8^+,均显著升高(P<0.01),NK 活性也明显增高(P<0.05)。提示:平消胶囊对晚期肺癌的化疗可能有一定的增效作用,能减轻血液毒副作用。通过提高化疗后患者外周血 NK 活性及部分纠正 T 细胞亚群的失衡状态,改善患者的细胞免疫功能,起到了补气扶正的作用。
